Any active autoimmune disease or a documented history of serious autoimmune disease within the past 5 years requiring immunosuppressive therapy.
Patients with autoimmune disease who are otherwise eligible must not have received steroid and immunosuppressive therapy within 28 days prior to registration
Active autoimmune disease requiring disease-modifying therapy at the time of Screening.
Primary or secondary immunodeficiency (including immunosuppressive disease, autoimmune disease [including autoimmune endocrinopathies, such as hypothyroidism, and insulin dependent diabetes mellitus], or usage of immunosuppressive medications).
Patients with chronic autoimmune disease(s) requiring systemic immunosuppression.
Subject has active, suspected, or previously documented autoimmune disease, defined as requiring systemic treatment.
Active autoimmune disease requiring immunosuppressive therapy
Patient with active autoimmune disease or any medical condition requiring the use of systemic immunosuppressive medications .
Active autoimmune condition requiring systemic immunosuppressive medication
Patients cannot have active autoimmune disease or immunosuppressive conditions
Patients with active autoimmune disease, requiring ongoing immunosuppressive therapy or history of transplantation
History of autoimmune disease resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years prior to enrollment
Uncontrolled autoimmune disease requiring active systemic treatment
Patients with active clinically significant autoimmune disease, defined as a history of requiring systemic immunosuppressive therapy and at ongoing risk for potential disease exacerbation. Patients with a history of autoimmune thyroid disease, asthma, or limited skin manifestations are potentially eligible.
Active autoimmune disease requiring systemic steroids or immunosuppressive agents within 7 days prior to study entry
Active autoimmune disease requiring immunosuppressive therapy
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune disease requiring ongoing systemic immunosuppressive therapy
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune disease requiring systemic immunosuppressive therapy.
Current autoimmune disease requiring >= 20 mg/day of prednisone or systemic immunosuppressive therapy (eg. with cyclosporine or azathioprine).
CRITERIA FOR LEUKAPHERESIS AND PRE-THERAPY EVALUATION: Active autoimmune disease requiring immunosuppressive therapy, unless considered by the PI or designee to be eligible
Active autoimmune disease requiring systemic immunosuppressive therapy
Active auto-immune disease including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the principal investigator) autoimmune disease requiring prolonged immunosuppressive therapy
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune disease requiring immunosuppressive therapy
History of autoimmune disease, requiring systemic immunosuppression and/or systemic disease modifying agents within the last 2 years
Active autoimmune diseases requiring systemic treatments
Active autoimmune disease and chronic inflammatory conditions requiring concurrent use of any systemic immunosuppressants or steroids.
Have active auto-immune disease, including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the principal investigator) autoimmune disease requiring prolonged immunosuppressive therapy
Prior organ transplant or autoimmune disease requiring immunosuppressive therapy
Active autoimmune disease requiring immunosuppressive therapy
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Active autoimmune disease requiring immunosuppressive therapy
EXCLUSION CRITERIA FOR TNBC: Active autoimmune disease requiring immunosuppressive therapy
Active autoimmune disease requiring disease-modifying therapy
History of severe autoimmune disease requiring steroids or other immunosuppressive treatments
Subjects must not have active auto-immune disease, including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the principal investigator) autoimmune disease requiring prolonged immunosuppressive therapy
Have any active disease requiring systemic immunosuppressive treatment
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune disease requiring immunosuppressive therapy is excluded unless discussed with the Principal Investigator (PI)
Known autoimmune disease requiring active treatment.
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune disease requiring immunosuppressive treatment or history of autoimmune disease requiring immunosuppressive therapy (e.g. requirement for systemic therapy with >10 mg/day prednisone-equivalent) or any other concurrent use of immunosuppressive therapy.
Active autoimmune disease requiring systemic immunosuppressive therapy
Participants that have experienced active autoimmune disorders requiring cytotoxic or immunosuppressive therapy within the 6 weeks (42 days) prior to consenting\r\n* The following will not be exclusionary:\r\n** The presence of laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody [ANA] titer) without symptoms\r\n** Clinical evidence of vitiligo\r\n** Other forms of depigmenting illness\r\n** Mild arthritis requiring nonsteroidal antiinflammatory drug (NSAID) medications
Current or history of systemic autoimmune disease requiring systemic therapy\r\n* NOTE: The following will not be exclusionary: \r\n** The presence of laboratory evidence of autoimmune disease (e.g., positive ANA titer) without associated symptoms \r\n** Clinical evidence of vitiligo \r\n** Other forms of depigmenting illness
Active (as defined by requiring immunosuppressive therapy) or history of clinically significant autoimmune disease (as defined by previously requiring immunosuppressive therapy)
Active autoimmune disease requiring systemic immunosuppressive therapy
Patients with a history of autoimmune disease that require immunosuppressive medications at the time of screening are excluded
Active autoimmune disease requiring treatment
Active or history of any autoimmune disease (except for subjects with vitiligo) or immunodeficiencies that required treatment with systemic immunosuppressive drugs
No disease requiring systemic immunosuppressive therapy
Active or prior autoimmune disease except for autoimmune thyroiditis, vitiligo, or psoriasis not requiring systemic therapy
Active autoimmune disease requiring disease modifying therapy
Patients with active autoimmune disease requiring disease-modifying therapy.
Subjects with active autoimmune disease requiring systemic immunosuppressive treatment within the past 4 weeks such as but not restricted to inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis; a history of autoimmune disease which is not active nor has required recent systemic immunosuppressive therapy (< 4 weeks prior to enrollment) is not reason for exclusion
Active autoimmune disease requiring systemic immunosuppressive therapy
Active autoimmune/inflammatory conditions requiring ongoing immunosuppressive therapy
Patients with any clinically significant autoimmune disease requiring active treatment
Prior allogeneic transplant 7. History of severe autoimmune disease requiring steroids or other immunosuppressive treatments.
Active autoimmune disease currently requiring therapy
Any immunodeficiency disease or immunocompromised state or active autoimmune disease or history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment
History of severe autoimmune disease requiring steroids or other immunosuppressive treatments
Patients with active autoimmune disease requiring disease-modifying therapy.
Subjects with active autoimmune disease or a history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment.
Active autoimmune disease or any medical condition requiring the use of systemic immunosuppressive medications;
DONOR: Autoimmune disease requiring immunosuppressive drugs for maintenance
Any active autoimmune disease requiring treatment (e.g. steroid, disease-modifying antirheumatic drugs, biologic agents, etc.)
Active autoimmune disease, symptoms or conditions except for vitiligo, type I diabetes, treated thyroiditis, asymptomatic laboratory evidence of autoimmune disease (e.g.: +ANA, +RF, antithyroglobulin antibodies), or mild arthritis requiring no therapy or manageable with NSAIDs.
Active autoimmune disease or condition requiring chronic immunosuppressive therapy
Autoimmune disease requiring immunosuppressive drugs for maintenance
DONOR: Autoimmune disease requiring immunosuppressive drugs for maintenance
Known history or evidence of brain metastases, immunodeficiency disease or immunocompromised state or history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment
No active (as defined by requiring immunosuppressive therapy) or history of clinically significant autoimmune disease (as defined by previously requiring immunosuppressive therapy)
Any immunodeficiency disease or immunocompromised state or active autoimmune disease or history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment
Active autoimmune disease requiring disease modifying therapy
Patients with active autoimmune conditions requiting systemic immunosuppressive therapy within the previous 5 years at not eligible
Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible
Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible
Any active autoimmune disease requiring treatment, with the exception of vitiligo
Active autoimmune disease requiring systemic immunosuppressive therapy (standard of care [SOC] GVHD prophylaxis is permitted)
Known immunosuppressive disease, autoimmune conditions, and /or chronic viral infections
Autoimmune disease resulting in end-organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years prior to enrollment
